Community-acquired Pneumonia
Conditions
Brief summary
This research is to evaluate the effect of different antibiotics (Moxifloxacin Hydrochloride and Sodium Chloride Injection vs. β-lactam antibiotics for injection +/- Azithromycin for Injection) on the early deterioration or progression (\<72 h of treatment) of community acquired pneumonia and to study the effect of the early deterioration or progression on the prognosis of community acquired pneumonia.
Interventions
DRUGMoxifloxacin Hydrochloride and Sodium Chloride Injection
Moxifloxacin group will be given Moxifloxacin Hydrochloride and Sodium Chloride Injection and β-lactams group will be given β-lactam antibiotics for injection +/- Azithromycin for Injection.
Sponsors
Peking Union Medical College Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age\>=18y. 2. Diagnosed with CAP. 3. Need hospitalization. 4. Receive Moxifloxacin Hydrochloride and Sodium Chloride Injection or β-lactam antibiotics for injection +/- Azithromycin for Injection as initial treatment. 5. Signed informed consent form.
Exclusion criteria
Patients who meet any of the following criteria will not be included in the study: 1. Pneumonia is aquired more than 48h after admission or the patient was admitted to hospital within 30 days prior to admission. 2. Start antibiotic treatment before admission. 3. Gestational period or suckling period. 4. Admitted to ICU. 5. Immunocompromised patients. 6. Pneumonia is the terminal event of a serious disease. 7. Tuberculosis, lung cancer, non-infectious interstitial lung disease, pulmonary edema, atelectasis, pulmonary embolism, pulmanory eosinophilia, pulmonary vasculitis. 8. Allergic to the antibiotics of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| early deterioration or progression rate | 3 days |
Countries
China
Contacts
Primary ContactJun Xu, MD
Outcome results
None listed